Oral Lichen Planus, Leptin Levels
Conditions
Keywords
salivary, Serum
Brief summary
This study aims to evaluate the levels of leptin in both saliva and serum samples of patients diagnosed with oral lichen.
Detailed description
Oral lichen planus is a frequently encountered chronic muco-cutaneous condition with a high prevalence rate. The condition can be classified as an autoimmune disorder.Although the exact cause of this condition is unknown, some potential risk factors should be taken into account, such as systemic disorders, psychogenic diseases, dental restorations, and certain medications. The oral lesions exhibit a mostly bilateral pattern, often manifesting in the inner buccal mucosa. The condition can be classified into three distinct forms, namely the reticular form, atrophic form, and bullous-erosive form. The condition is classified as a premalignant lesion due to its significant likelihood of undergoing malignant transformation. The disease is characterized by the presence of T-lymphocyte infiltration in the basal cell layer of the epithelium and the presence of cytoid bodies, which are distinct histopathologic markers. Leptin, a hormone generated by adipocytes, is involved in immunological responses and contributes to the development of autoimmunity. The presence of dyslipidemia has been found to be associated with lipoprotein (LP) abnormalities. Consequently, this study was undertaken to assess the blood leptin levels and lipid profile in individuals with LP. Leptin, a polypeptide hormone, is produced and released by white adipose tissue. Multiple research have substantiated an increase in leptin levels among persons exhibiting elevated body mass index (BMI) and a higher percentage of total body fat. Additionally, it is involved in the cellular immune response and facilitates the development of autoimmunity. There is a proposition suggesting that leptin has a role in the promotion of cytokine generation and modulation of helper T cells, potentially implicating its involvement in the pathogenesis of psoriasis. The available information about leptin status in dermatological illnesses other than psoriasis is currently sparse. It is plausible that it may have a significant role in the pathogenesis of lichen planus. However, there is a lack of literature regarding the levels of leptin in LP. There is an association between dyslipidemia and LP. Numerous investigations have consistently demonstrated notable deviations in lipid profile levels between individuals with LP and those in normal, healthy control cohorts. These findings have led researchers to posit a correlation between chronic inflammation and dyslipidemia, hence heightening the susceptibility to cardiovascular illnesses. The potential impact of leptin on the progression of LP is being investigated. The objective of this study was to conduct a comparative analysis of blood leptin levels between individuals recently diagnosed with LP and a control group consisting of healthy individuals. Additionally, an assessment was conducted to examine the correlation between leptin levels, lipid profile, and the length of illness.
Interventions
DIAGNOSTIC_TESTLeptin
Assessment of salivary and serum leptin levels in oral lichen planus patients and healthy controls
Sponsors
Cairo University
Study design
Observational model
CASE_CONTROL
Time perspective
OTHER
Eligibility
Sex/Gender
ALL
Age
30 Years to 70 Years
Healthy volunteers
Yes
Inclusion criteria
* Ages for both sexes fall between 30 and 70. * Symptomatic OLP has been diagnosed clinically and verified histologically. * Participants who sign a written consent form after being fully informed about the study.
Exclusion criteria
* Treatment with a systemic or locally administered systemic medication within the previous three months before the commencement of the research. * Patients now taking or who have just stopped taking an NSAIDs (both steroidal and non steroidal) for pain or inflammation. * Patients who have been diagnosed with a malignant tumor or tumors. * Women who are expecting or nursing. * Inmates, the mentally ill, the elderly, etc, all fall into this category.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Serum Leptin Level | Baseline | Assessment of serum leptin levels in in oral lichen planus patients |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Salivary Leptin Levels | Baseline | Assessment of salivary leptin levels in oral lichen planus patients |
Countries
Egypt
Participant flow
Recruitment details
The recruitment process has taken 1 year, starting from December 2023 till December 2024; all recruitment processes were done in the Cairo University outpatient clinic.
Pre-assignment details
There is no washout that has been done; some of the enrolled participants were excluded because they were currently on systemic steroid medication or taking topical steroids for lesions.
Participants by arm
| Arm | Count |
|---|---|
| Oral Lichen Planus Patients Assessment of salivary and serum leptin levels
Leptin: Assessment of salivary and serum leptin levels in oral lichen planus patients and healthy controls | 39 |
| Healthy Control Group Assessment of salivary and serum leptin levels
Leptin: Assessment of salivary and serum leptin levels in oral lichen planus patients and healthy controls | 39 |
| Total | 78 |
Baseline characteristics
| Characteristic | Oral Lichen Planus Patients | Healthy Control Group | Total |
|---|---|---|---|
| Age, Categorical <=18 years | 0 Participants | 0 Participants | 0 Participants |
| Age, Categorical >=65 years | 8 Participants | 1 Participants | 9 Participants |
| Age, Categorical Between 18 and 65 years | 31 Participants | 38 Participants | 69 Participants |
| Age, Continuous | 50.77 years STANDARD_DEVIATION 13.37 | 34.51 years STANDARD_DEVIATION 12.53 | 42.641 years STANDARD_DEVIATION 12.87 |
| Body mass index | 28.47 Kg/m^2 STANDARD_DEVIATION 3.95 | 28.77 Kg/m^2 STANDARD_DEVIATION 3.32 | 28.62 Kg/m^2 STANDARD_DEVIATION 3.62 |
| Race and Ethnicity Not Collected | — | — | 0 Participants |
| Region of Enrollment Egypt | 39 Participants | 39 Participants | 78 Participants |
| Sex: Female, Male Female | 26 Participants | 21 Participants | 47 Participants |
| Sex: Female, Male Male | 13 Participants | 18 Participants | 31 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | 0 / 39 | 0 / 39 |
| other Total, other adverse events | 0 / 39 | 0 / 39 |
| serious Total, serious adverse events | 0 / 39 | 0 / 39 |
Outcome results
Primary
Serum Leptin Level
Assessment of serum leptin levels in in oral lichen planus patients
Time frame: Baseline
Population: Levels of leptin in serum of patients with active oral lichen planus
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Serum Leptin Levels in OLP Patients | Serum Leptin Level | 13.23 ng/ml | Standard Deviation 7.29 |
| Serum Leptin Levels in Healthy Control Subjects | Serum Leptin Level | 4.20 ng/ml | Standard Deviation 1.23 |
Secondary
Salivary Leptin Levels
Assessment of salivary leptin levels in oral lichen planus patients
Time frame: Baseline
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Serum Leptin Levels in OLP Patients | Salivary Leptin Levels | 15.31 ng/ml | Standard Deviation 6.59 |
| Serum Leptin Levels in Healthy Control Subjects | Salivary Leptin Levels | 4.90 ng/ml | Standard Deviation 1.26 |